ATP5PB

Across TCGA pan-cancer cohorts, ATP5PB Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ATP5PB data layer compared with 19 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher ATP5PB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ATP5PB expression acts as an unfavorable survival marker.

CESC, BLCA, and SKCM are the cancer types where ATP5PB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.047	0.830	<.001	12	view →
BLCA	DFS	Median	All	0.191	0.627	.010	12	view →
SKCM	OS	Median	All	0.145	0.781	<.001	9	view →
COAD	DFS	Median	All	0.415	0.785	.017	8	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ATP5PB–CESC (OS)

Open the CESC breakdown →